

Hikma further improves its environmental performance in 2019 CDP Global Climate Change Report

Company Exceeds European Average and Improves Previous Ranking

London, February 3, 2020 – Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1/stable Moody's and BB+/positive S&P), the multinational generic pharmaceutical company, has received a 'B' rating from the CDP 2019 Global Climate Change Report, marking an improvement over the company's most recent score, and placing it above the European CDP average.

CDP is an independent, not-for-profit organization aimed at enabling companies to progress towards environmental stewardship through benchmarking and comparison with peers.

Hikma was recognized for its emission reduction initiatives, governance and risk management processes, demonstrating its strong commitment and leadership in these areas. The company also received higher-than-average marks for its work around risk disclosure, opportunity disclosure and business impact/financial planning.

"We are proud to receive this acknowledgement of the positive impact of the efforts we've made to improve our environmental performance," explained Hana Ramadan, Vice President of Corporate Social Responsibility at Hikma. "We have amplified our efforts around sustainability, in particular to make an immediate reduction on our energy consumption levels. The recent improved score from the CDP is an important recognition of these focused efforts."

As part of Hikma's 'Go Green' initiative in 2019, the company successfully completed its installation of PV/net metering solar panels that absorb a portion of overall energy needs at facilities in Jordan and Portugal, installed charging stations for electric vehicles at company facilities, switched its fleet of company vehicles to hybrid-powered vehicles and moved to cleaner fuel options. The company has also elevated sustainability issues to the Compliance, Responsibility and Ethics Committee (CREC) to ensure greater Board oversight of impact efforts.

To learn more about the sustainability work at Hikma, please visit <https://www.hikma.com/sustainability/>.

- ENDS -

Enquiries

Hikma Pharmaceuticals PLC

Brooke Clarke
Communications and Corporate Affairs

+44 (0)20 7399 2795/ +44 7970338250
media@hikma.com

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-



branded generic medicines. Together, our 8,400 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com